Navin Fluorine Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹39,245 Cr
- Book Value
- ₹775
- Stock P/E
- 60.6
- Dividend Yield
- 0.20%
- ROE
- 19.6%
- ROCE
- 21.0%
- PEG Ratio
- 2.83
- EV/EBITDA
- 35.8
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Navin Fluorine International Ltd closed at ₹8,530.00 on 3 November 2026, up 1.5% on the day, 1.6% above its 50-day average, 4.7% below its 52-week high, with volume at 1.16× its 20-session average.
- RSI 14
- 55.3
- vs 50-day SMA
- +1.6%
- vs 200-day SMA
- +16.7%
- From 52-week high
- -4.7%
- Relative volume
- 1.16×
- 20-day return
- -0.1%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
What the exchange files show
NSE EOD ·Navin Fluorine International Ltd settled 45.1% of its traded volume as delivery on 3 November 2026, against a median of 53.1% across 109 sessions since 29 May 2026, below the 46.1% median for liquid NSE shares that day.
NSE's sec_list file assigns Navin Fluorine International Ltd no daily price band — the marking carried by securities in the derivatives segment.
- Delivery, latest
- 45.1%
- Delivery, 109-session median
- 53.1%
- Delivery range
- 14.8–81.6%
- Daily price band
- None (F&O)
- Close x volume, latest
- ₹148 cr
- Series
- EQ
Corporate actions
- 5 Nov 2026 — Interim Dividend - Rs 8 Per Share
- 12 Jun 2026 — Dividend - Rs 8.60 Per Share
- 7 Nov 2025 — Interim Dividend - Rs 6.50 Per Share
Prices, delivery and the price band come from NSE's published end-of-day files (sec_bhavdata_full and sec_list), covering 109 sessions from 29 May 2026. Surveillance status, disclosed deals and corporate actions come from separate NSE feeds on their own schedules and are not bounded by that window. Descriptive exchange data, not investment advice. What delivery percentage does and does not tell you →
Navin Fluorine share price today
Navin Fluorine (NSE: NAVINFLUOR) works the periodic table’s most difficult column. Fluorine chemistry — corrosive, dangerous, capital-hungry — has a global shortage of practitioners, and molecules containing fluorine are exactly what agrochemical and pharma innovators increasingly design. Navin’s stack runs from legacy refrigerants through specialty fluorochemicals to a CDMO arm making patented fluorinated molecules for global innovators.
After a leadership transition and a capex digestion phase, execution has re-accelerated — new plants commissioning, CDMO order momentum returning. At 60.6×, scarcity chemistry deserves a premium, but this valuation still prices flawlessness.
Scarce chemistry, long contracts
The moat is handling competence: fluorine’s danger is the barrier to entry. Once an innovator qualifies Navin for a patented molecule, switching is a multi-year regulatory event — CDMO revenue is annuity-shaped. The specialty book (agro intermediates, performance materials) rides the same fluorination trend, and refrigerant transitions (HFC phase-downs) keep the legacy business cash-generative through regulatory scarcity.
Watch-items: CDMO order cadence (lumpy by nature), capex commissioning timelines (D/E 0.32 reflects the build-out), the relatively low 27% promoter holding, and agrochem-cycle softness in specialty volumes.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹39,245 Cr |
| P/E (TTM) | 60.6 |
| EV/EBITDA | 35.8 |
| Operating margin | 32.6% |
| ROE / ROCE | 19.6% / 21.0% |
| Debt to equity | 0.32 |
| Sales CAGR (5y) | 23.0% |
| Profit CAGR (5y) | 21.4% |
| Promoter holding | 27.1% |
| EPS (TTM) | ₹126.0 |
Navin Fluorine share price target 2026 to 2030
EPS base ₹126.0 (TTM). Bear: agro cycle drags and CDMO stays lumpy — 10% growth, multiple at 34×. Base: new capacity fills and CDMO compounds — 17% growth at 46×. Bull: fluorination demand outruns global supply — 23% growth at 58×.
From ₹7,629, the base case is ≈ +67% over four and a half years; the bear is −10%. Scarce chemistry supports the franchise, but project timing, utilisation and the exit multiple remain decisive.
Reasons to own Navin Fluorine (at the right price)
- Fluorine-handling competence is a global scarcity — the barrier is danger itself.
- CDMO annuities: patented-molecule contracts with multi-year switching costs.
- 32.6% operating margins evidence real pricing power, not capacity arbitrage.
- The capex wave is commissioning — revenue arrives as depreciation peaks.
- Fluorinated-molecule design trends in agro and pharma are decade-length.
The risks: 60× with 21% ROCE leaves the multiple doing heavy lifting, promoter holding at 27% invites speculation each cycle, and CDMO lumpiness makes quarters unpredictable.
What to weigh at the current price
Navin Fluorine’s scarce chemistry and CDMO relationships deserve a premium, but 60.6× earnings still assumes smooth commissioning and order conversion. Capex utilisation, CDMO cadence and leverage will decide whether the premium is earned.
FAQ
What is the Navin Fluorine share price target for 2030? The table above presents bear, base and bull paths through 2030. Each depends on the stated EPS-growth and valuation assumptions; none is a guaranteed outcome.
Why is fluorine chemistry so defensible? Hydrofluoric acid handling is lethal when done wrong — decades of safety competence, specialised plants and regulatory records form a moat capital alone cannot buy.
What is the CDMO business here? Contract development and manufacturing of fluorinated molecules still under patent, for global agro/pharma innovators — qualified-supplier annuities, not generic competition.
When are Navin Fluorine’s next results? Check the results calendar and confirm the announced date in the exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.